Cetilistat approval puts Takeda first in Japan obesity market
This article was originally published in Scrip
Executive Summary
The history of drug development for obesity in Japan is strewn with product casualties but Takeda has cleared a significant hurdle with the formal approval in this market of the lipase inhibitor Oblean (cetilistat).